deltatrials
No Longer Available EXPANDED_ACCESS NCT02570412

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

Compassionate Use of Aldoxorubicin in Sarcoma Patients Who Have Failed Prior Chemotherapy

Sponsor: CytRx

Conditions Sarcoma
Interventions aldoxorubicin
Updated 7 times since 2017 Last updated: Oct 21, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Sarcoma and is currently ongoing. CytRx leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotNo Longer Available~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshotNo Longer Available~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotNo Longer Available~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotNo Longer Available~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotNo Longer Available~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotNo Longer Available~Sep 2024 – present · 24 months · monthly snapshotNo Longer Available

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    No Longer Available

  2. Jul 2024 — Sep 2024 [monthly]

    No Longer Available

  3. Jan 2021 — Jul 2024 [monthly]

    No Longer Available

  4. Jun 2018 — Jan 2021 [monthly]

    No Longer Available

  5. Apr 2018 — Jun 2018 [monthly]

    No Longer Available

    Phase: NANone

Show 2 earlier versions
  1. Feb 2017 — Apr 2018 [monthly]

    No Longer Available NA

  2. Jan 2017 — Feb 2017 [monthly]

    No Longer Available NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CytRx
Data source: CytRx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations